Patient preference evidence can strengthen HTA submissions
How patient preference evidence helped show the value of infectious disease prevention beyond clinical outcomes.
en
Choose automatic translation:
Director
Elise holds an MSc in Bio-Pharmaceutical Sciences and is a Healthcare Director at SKIM. With more than 18 years of experience in healthcare insights consulting, she helps global pharma and MedTech companies turn customer insights into confident strategic decisions. Her expertise includes advanced quantitative research, hybrid research approaches, demand forecasting, and strategic decision support across the product lifecycle, from early development and launch planning through commercialization. Passionate about understanding patient and healthcare professional decision-making, Elise translates complex evidence into clear, actionable recommendations that drive business impact.
How patient preference evidence helped show the value of infectious disease prevention beyond clinical outcomes.
Practical tips for pharma marketers to accelerate digital marketing strategies now. How to adapt HCP multichannel marketing during and post-disruption